European healthtech dealmaking expected to accelerate through 2027
European healthtech M&A is expected to accelerate into 2027 as private equity deploys record healthcare funds and strategic buyers seek AI and data capabilities. The article highlights the European Health Data Space as a regulatory driver making interoperability a purchasing requirement. It also notes recent deals such as Hims & Hers/Eucalyptus, RadNet/DeepHealth/Gleamer, and Sectra/Oxipit.
European healthtech mergers and acquisitions are projected to gain pace through 2027. Private equity has amassed large healthcare funds that must be invested and returned, while strategic buyers increasingly prefer acquiring artificial-intelligence and data assets over building them internally. The European Health Data Space is a key regulatory catalyst, making interoperability a purchasing requirement for EU providers.
Recent examples include Hims & Hers’ up-to-$1.15bn purchase of Eucalyptus, RadNet’s DeepHealth acquiring Paris-based Gleamer, and Sectra’s acquisition of Lithuanian radiology-AI firm Oxipit. Global healthtech deal volume reached 149 in Q1 2026, versus 555 for all of 2025, with private equity involved in about one-third of transactions.
The expected wave of healthtech consolidation could affect patients, clinicians, hospitals, startups and investors. Larger buyers may accelerate AI and data tools, potentially improving diagnostics, documentation and care coordination. Yet fewer independent vendors could reduce choice and concentrate sensitive health data, so EHDS and AI Act safeguards may shape whether benefits are broadly shared.